Loading...
XNAS
BNBX
Market cap487kUSD
Jul 09, Last price  
0.38USD
1D
8.35%
1Q
-34.93%
Jan 2017
-79.60%
IPO
-86.02%
Name

Applied DNA Sciences Inc

Chart & Performance

D1W1MN
XNAS:BNBX chart
P/E
P/S
0.23
EPS
Div Yield, %
Shrs. gr., 5y
21.45%
Rev. gr., 5y
2.04%
Revenues
2m
-37.72%
18,900121,920873,010295,162519,844968,8481,854,6942,036,2222,721,2249,008,4994,186,4274,751,2603,903,3435,389,0891,931,4979,027,73818,168,67713,367,4433,431,4202,136,935
Net income
-15m
L+116.81%
-2,410,237-13,304,833-6,802,8983,944,578-7,909,600-10,515,124-7,150,712-17,686,472-13,066,661-11,881,137-12,175,979-12,855,767-11,692,928-8,632,446-12,764,974-14,286,442-8,267,891-9,947,059-6,992,521-15,160,724
CFO
-13m
L-8.70%
-2,883,815-2,251,580-2,926,280-2,468,598-2,455,189-3,761,716-3,960,679-7,870,353-8,512,738-6,965,846-9,896,727-7,479,184-6,917,209-6,861,772-11,143,059-13,387,955-8,976,706-6,217,677-13,711,397-12,518,695

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Applied DNA Sciences, Inc. specializes in devising and marketing sophisticated DNA-centric technological solutions across diverse sectors. Its activities encompass nucleic acid-based in vitro diagnostics and the preclinical development and production of nucleic acid-based pharmaceuticals. Furthermore, the company offers robust solutions for bolstering supply chain security, combating counterfeiting, and preventing theft. Key offerings for product authenticity and supply chain integrity include SigNature molecular tags, which imbue products with forensic traceability and protection, thereby strengthening brand defense and supply chain resilience while aiding in criminal identification and prosecution. To facilitate real-time, field-based verification of these tags, they provide SigNify IF portable DNA readers along with corresponding SigNify consumable reagent test kits. The CertainT platform represents a holistic approach, integrating tagging, testing, and tracking capabilities, empowering manufacturers, brands, and trade organizations to substantiate their product claims with verifiable evidence. Within the diagnostic realm, the company produces the LineaTM COVID-19 Assay Kit, a PCR-based molecular diagnostic test. It also offers the safeCircle COVID-19 diagnostic kit, specifically designed to help curtail viral transmission within communal settings such as schools or workplaces. Additionally, Applied DNA Sciences delivers contract research and manufacturing services for the burgeoning nucleic acid-based therapeutic markets during their preclinical phases. This extends to providing contract research for clients involved in preclinical studies of RNA-based drugs and biologics. The company is also at the forefront of developing an innovative technology for the capture and identification of invasive circulating tumor cells, utilizing a proprietary functional assay to isolate live invasive tumor cells and their associated lymphocytes. Operating internationally, the firm maintains a significant footprint across the United States, Europe, and Asia. Founded in 1983, the organization was initially known as Datalink Systems, Inc., before officially changing its name to Applied DNA Sciences, Inc. in 2002. Its corporate headquarters are located in Stony Brook, New York.
IPO date
Aug 24, 2001
Employees
61
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑092024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT